Jane Street Group LLC Invests $521,000 in Radius Health Inc (RDUS) Stock
Jane Street Group LLC bought a new position in shares of Radius Health Inc (NASDAQ:RDUS) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 31,598 shares of the biopharmaceutical company’s stock, valued at approximately $521,000.
Other large investors have also recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY boosted its stake in shares of Radius Health by 395.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,549 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 10,812 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Radius Health during the 4th quarter worth about $218,000. Two Sigma Investments LP acquired a new stake in shares of Radius Health during the 4th quarter worth about $981,000. Pura Vida Investments LLC acquired a new stake in shares of Radius Health during the 4th quarter worth about $942,000. Finally, Geode Capital Management LLC boosted its stake in shares of Radius Health by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 457,063 shares of the biopharmaceutical company’s stock worth $7,536,000 after purchasing an additional 36,093 shares during the last quarter.
RDUS opened at $22.22 on Wednesday. The company has a debt-to-equity ratio of 2.97, a quick ratio of 5.79 and a current ratio of 5.92. Radius Health Inc has a 1 year low of $12.81 and a 1 year high of $36.94. The company has a market capitalization of $1.02 billion, a P/E ratio of -4.55 and a beta of 0.95.
RDUS has been the topic of several analyst reports. BidaskClub raised shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research cut shares of Radius Health from a “buy” rating to a “hold” rating in a research note on Tuesday, December 11th. ValuEngine cut shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Finally, HC Wainwright initiated coverage on shares of Radius Health in a research note on Thursday, February 14th. They set a “neutral” rating and a $22.00 price target on the stock. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $37.17.
Radius Health Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Further Reading: Do back-end load funds outperform no-load funds?
Want to see what other hedge funds are holding RDUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Radius Health Inc (NASDAQ:RDUS).
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.